血清25-羟维生素D浓度与2型糖尿病患者痴呆风险的关联:英国生物银行队列研究
该队列研究纳入英国生物银行中13,486名≥60岁、招募时无痴呆的2型糖尿病患者,随访平均8.5年。血清25(OH)D≥50 nmol/L者较严重缺乏(<25 nmol/L)者全因痴呆风险显著降低(HR 0.41,95%CI 0.29-0.60)。
要点
- 2型糖尿病患者中血清25(OH)D与全因痴呆、阿尔茨海默病和血管性痴呆风险呈非线性负相关,阈值约50 nmol/L。
- 与严重缺乏(<25 nmol/L)者相比,25(OH)D≥50 nmol/L者全因痴呆HR 0.41(95%CI 0.29-0.60)。
- 该关联为观察性发现,作者指出若经重复验证,可能对通过改善维生素D水平预防痴呆的策略有参考意义。
核心结论
- 在2型糖尿病患者中,较高的血清25(OH)D浓度与全因痴呆、阿尔茨海默病和血管性痴呆风险降低显著相关。
- 作者指出,若该发现经重复验证,可能对针对改善或维持2型糖尿病患者血清维生素D浓度的痴呆预防策略有参考意义。
研究设计与样本
- 研究为英国生物银行队列研究,纳入13,486名≥60岁、招募时(2006-2010年)无痴呆的2型糖尿病患者。
- 招募时采用化学发光免疫分析法测定血清25(OH)D浓度,依据内分泌学会临床实践指南将≥75 nmol/L定义为充足。
- 通过电子健康记录确定全因痴呆、阿尔茨海默病和血管性痴呆病例,风险人年从招募日期计算至痴呆报告、死亡、失访或2018年2月28日中最早发生者。
- 13,486名2型糖尿病患者平均年龄64.6岁,男性占64.3%;38.3%维生素D≥50 nmol/L,仅9.1%≥75 nmol/L。
- 平均随访8.5年,观察到283例全因痴呆,其中阿尔茨海默病101例、血管性痴呆97例。
主要发现
- 限制性立方样条分析显示血清25(OH)D与全因痴呆风险呈非线性关系(P非线性<0.001),与血管性痴呆呈非线性关系(P非线性=0.007),与阿尔茨海默病的非线性关联为临界显著性(P非线性=0.06),所有结局的阈值约在50 nmol/L。
- 与严重缺乏(25(OH)D<25 nmol/L)者相比,25(OH)D≥50 nmol/L者全因痴呆的多变量HR为0.41(95%CI 0.29-0.60,P趋势<0.001)。
- 与严重缺乏(25(OH)D<25 nmol/L)者相比,25(OH)D≥50 nmol/L者阿尔茨海默病的多变量HR为0.50(95%CI 0.27-0.92,P趋势=0.06)。
- 与严重缺乏(25(OH)D<25 nmol/L)者相比,25(OH)D≥50 nmol/L者血管性痴呆的多变量HR为0.41(95%CI 0.22-0.77,P趋势=0.01)。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 当前分析的主要局限性是痴呆病例通过电子健康记录识别,可能存在漏报。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several epidemiological studies have suggested that vitamin D status is associated with risk of dementia in general populations. However, due to the synergistic effect between diabetic pathology and neuroinflammation, and the prothrombotic profile in patients with diabetes, whether vitamin D is associated with risk of dementia among patients with diabetes is unclear. This study aimed to investigate the associations of circulating vitamin D levels with risks of all-cause dementia, Alzheimer disease (AD), and vascular dementia (VD) among adults with type 2 diabetes (T2D). METHODS AND FINDINGS: This study included 13,486 individuals (≥60 years) with T2D and free of dementia at recruitment (2006-2010) from the UK Biobank study. Serum 25-hydroxyvitamin D (25[OH]D) concentrations were measured using the chemiluminescent immunoassay method at recruitment. Serum 25(OH)D ≥ 75 nmol/L was considered sufficient, according to the Endocrine Society Clinical Practice Guidelines. Incidence of all-cause dementia, AD, and VD cases was ascertained using electronic health records (EHRs). Each participant's person-years at risk were calculated from the date of recruitment to the date that dementia was reported, date of death, date of loss to follow-up, or 28 February 2018, whichever occurred first. Among the 13,486 individuals with T2D (mean age, 64.6 years; men, 64.3%), 38.3% had vitamin D ≥ 50 nmol/L and only 9.1% had vitamin D ≥ 75 nmol/L. During a mean follow-up of 8.5 years, we observed 283 cases of all-cause dementia, including 101 AD and 97 VD cases. Restricted cubic spline analysis demonstrated a nonlinear relationship between serum 25(OH)D and risk of all-cause dementia (Pnonlinearity < 0.001) and VD (Pnonlinearity = 0.007), and the nonlinear association reached borderline significance for AD (Pnonlinearity = 0.06), with a threshold at around a serum 25(OH)D value of 50 nmol/L for all the outcomes. Higher serum levels of 25(OH)D were significantly associated with a lower risk of all-cause dementia, AD, and VD. The multivariate hazard ratios and 95% confidence intervals for participants who had serum 25(OH)D ≥ 50 nmol/L, compared with those who were severely deficient (25[OH]D < 25 nmol/L), were 0.41 (0.29-0.60) for all-cause dementia (Ptrend < 0.001), 0.50 (0.27-0.92) for AD (Ptrend = 0.06), and 0.41 (0.22-0.77) for VD (Ptrend = 0.01). The main limitation of the current analysis was the potential underreporting of dementia cases, as the cases were identified via EHRs. CONCLUSIONS: In this study, we observed that higher concentrations of serum 25(OH)D were significantly associated with a lower risk of all-cause dementia, AD, and VD among individuals with T2D. Our findings, if confirmed by replication, may have relevance for dementia prevention strategies that target improving or maintaining serum vitamin D concentrations among patients with T2D.
引用
- Geng T, Lu Q, Wan Z, et al. Association of serum 25-hydroxyvitamin D concentrations with risk of dementia among individuals with type 2 diabetes: A cohort study in the UK Biobank. PLoS Med. 2022. PMID: 35025861. doi:10.1371/journal.pmed.1003906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。